Cryoport reports second quarter 2024 financial results

Revenue improved sequentially across all businesses commercial cell & gene therapy revenue increased 51% year-over-year and 20% sequentially a record total of 684 global clinical trials supported as of june 30, 2024 cost reduction initiatives anticipated to result in approximately $22 million of annualized cost savings and drive cryoport towards its goal of profitable growth, as well as a return to positive adjusted ebitda in 2025 company provides updated 2024 full-year revenue guidance of $225 to $235 million nashville, tenn. , aug. 6, 2024 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) (cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for its second quarter (q2) and first half (h1) of 2024.
CYRX Ratings Summary
CYRX Quant Ranking